Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903121 · ClinicalTrials.gov registry record · Phase 4
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
A Phase 4 study of Bleeding and Breakthrough Bleeding, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 109
- Enrollment target
- 1
- Study location
NCT02903121 is a Phase 4 study of Bleeding and Breakthrough Bleeding that has completed, run by Oregon Health and Science University. The registered enrollment target is 109 participants, below the 1,480-participant average among 23 other Bleeding trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02903121, a Phase 4 study of Bleeding and Breakthrough Bleeding, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 109 participants
- Enrollment target
- 1
- Study location
Study Summary
The etonogestrel (ENG) subdermal contraceptive implant (ENG implant) is a highly effective method of preventing pregnancy, but it has bleeding side effects that make it unappealing for many women. The only study to demonstrate a sustained reduction in bleeding lasting for two months was the selective estrogen receptor modulator (SERM) tamoxifen in users of the levonogestrel (LNG) contraceptive implant. Based on the investigators encouraging preliminary data of tamoxifen and ENG implant users, the investigators plan to perform additional studies on the impact of tamoxifen on the breakthrough bleeding experience by ENG implant users.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tamoxifen
- DRUG Tamoxifen (open label)
Study Locations (1)
Oregon
- OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2017-01-20 |
| Est. Completion | 2019-06-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02903121
The ClinicalTrials.gov registry entry for NCT02903121 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,480-participant average among 23 other Bleeding trials with a reported enrollment target (93% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bleeding appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02903121 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02903121 about?
NCT02903121 is a clinical study titled "Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users". The etonogestrel (ENG) subdermal contraceptive implant (ENG implant) is a highly effective method of preventing pregnancy, but it has bleeding side effects that make it unappealing for many women. The only study to demonstrate a sustained reduction in bleeding lasting for two months was the selectiv...
What is the current status of trial NCT02903121?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 109 participants. The study started on 2017-01-20. Estimated completion is 2019-06-05.
What conditions does trial NCT02903121 study?
This clinical trial studies the following conditions: Bleeding, Breakthrough Bleeding, Implants.
What interventions are being tested in trial NCT02903121?
The interventions under investigation include: Placebo (DRUG), Tamoxifen (DRUG), Tamoxifen (open label) (DRUG).
Who is sponsoring clinical trial NCT02903121?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02903121 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
RECRUITING · Phase 4
-
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
COMPLETED · Phase 4
-
Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
COMPLETED · Phase 4
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
RECRUITING
-
Quantra Point-of-Care Hemostasis Monitoring
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.